Document is current
Any future updates will be listed below
-
Authors
Diab, Adi
Curti, Brendan
Bilen, Mehmet
Brohl, Andrew
Domingo-Musibay, Evidio
Borazanci, Erkut
Fanton, Christie
Haglund, Cat
Vimal, Mona
Muhsin, Mann
Marcondes, Mario
Nguyen, Anh
Tagliaferri, Mary
Lin, Wei
Zalevsky, Jonathan
D’Angelo, Sandra
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03435640 at ClinicalTrials.govDocuments that mention this clinical trial
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT
https://doi.org/10.1136/jitc-2021-004218
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
https://doi.org/10.1136/jitc-2020-sitc2020.0451
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0368
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
596 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
https://doi.org/10.1136/jitc-2021-sitc2021.596
- License Information
